Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Arthritis Research & Therapy

Figure 4

From: The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis

Figure 4

The effect of WAY-169916 in spleen cells. (a) The regulation of LBS binding protein (LBP), haptoglobin and S100A9 gene expression by WAY-169916 from spleens from the rat adjuvant model were confirmed by real-time RT–PCR (grey bars) compared with the regulation observed in the gene-profiling experiments (black bars). Results are expressed as means ± SEM from six rats per group. *P < 0.05 compared with vehicle control. (b) Treatment with WAY-169916 does not interfere with the binding of NF-κB to DNA. Nuclear extracts from primary mouse spleen cell cultures were co-treated for 18 hours with vehicle or concanavalin A (ConA; 5 μg/ml) and either WAY-169916 (1 μM) or pyrrolidine dithiocarbamate (PDTC) (100 μM) as indicated. CFA, complete Freund's adjuvant.

Back to article page